ArticleNutrition & metabolism2019
Plasma acylcarnitines could predict prognosis and evaluate treatment of IgA nephropathy.
Article in Nutrition & metabolism, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 23 citations in OpenAlex.
- Application of CLIR-Based Post-Analytical Tools to Dutch NBS Data Demonstrates Its Potential Impact on the Performance of CPT1, GA-1, IVA and MSUD Screening in a Disorder-Specific Way.International journal of neonatal screening · 2026Article
- Plasma acylcarnitine profiling reveals heart failure-specific fatty acid oxidation signature in chronic kidney disease.Journal of lipid research · 2026Article
- Lipidomic profiling reveals medium-chain acylcarnitines alterations as metabolic signatures in IgA nephropathy.BMC nephrology · 2026Article
- The clinical value of metabolic indicators in immunoglobulin A nephropathy.Frontiers in medicine · 2026Article
- Comprehensive and quantitative urinary metabolomic profiling for improved characterization of diabetic nephropathy.Metabolomics : Official journal of the Metabolomic Society · 2025Article
- Targeted Analysis of Serum and Urinary Metabolites for Early Chronic Kidney Disease.International journal of molecular sciences · 2025Article
- Article
- Albumin-to-fibrinogen ratio is an independent predictor of corticosteroid response and prognosis in patients with IgA nephropathy.European journal of medical research · 2023Article
- Article
- High-coverage targeted lipidomics could reveal lipid alterations and evaluate therapeutic efficacy of membranous nephropathy.Nutrition & metabolism · 2022Article
- Acylcarnitines: Can They Be Biomarkers of Diabetic Nephropathy?Diabetes, metabolic syndrome and obesity : targets and therapy · 2022Review
- The metabolomic differential plasma profile between dialysates. Pursuing to understand the mechanisms of citrate dialysate clinical benefits.Frontiers in physiology · 2022Article
- Lipidomics reveals association of circulating lipids with body mass index and outcomes in IgA nephropathy patients.Journal of molecular cell biology · 2021Article
- Amino Acid Metabolites Associated with Chronic Kidney Disease: An Eight-Year Follow-Up Korean Epidemiology Study.Biomedicines · 2020Article
- Reduced 24-h Sodium Excretion Is Associated With a Disturbed Plasma Acylcarnitine Profile in Vasovagal Syncope Children: A Pilot Study.Frontiers in pediatrics · 2020Article
- Altered Serum Amino Acid and Acylcarnitine Profiles in Hyperinsulinemic Hypoglycemia and Ketotic Hypoglycemia.Frontiers in endocrinology · 2020Article
- Monitoring Immune Responses in IgA Nephropathy: Biomarkers to Guide Management.Frontiers in immunology · 2020Review
- Remote ischaemic preconditioning influences the levels of acylcarnitines in vascular surgery: a randomised clinical trial.Nutrition & metabolism · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEffective evaluation or prediction of therapy response could be helpful for treatment of chronic kidney disease (CKD), which may rely on accurate biomarkers. Acylcarnitines are involved with lipid metabolism and mitochondrial function. The relation of acylcarnitines with treatment response in patients with CKD is unknown. The purpose of this study is to investigate the association of plasma acylcarnitines with renal function and its alteration by intervention in patients with IgA nephropathy (IgAN).
methodsA retrospective study was performed in 81 IgAN patients with treatment by traditional Chinese medicine (TCM). Multivariate linear regression analyses were performed to identify the association of acylcarnitines with baseline estimated glomerular filtration rate (eGFR) and eGFR changes after treatment.
resultsTwenty-seven acylcarnitines were measured at baseline and after 1-year TCM intervention. Certain short-chain and median-chain acylcarnitines were independently associated with baseline eGFR and eGFR alterations after 1 year treatment. Particularly, patients with high C5:1(β = - 0.42), C8:1(β = - 0.49), C3DC(β = - 0.5), C10:1(β = - 0.36) and C5DC(β = - 0.64)at baseline would have worse prognosis and treatment response. Moreover, certain acylcarnitines could be changed along with the eGFR alteration after 1-year TCM treatment.
conclusionsThe findings indicate a significant association between plasma acylcarnitines with prognosis and treatment responses in patients with IgAN, which suggest its role as a potential penal of biomarker for IgAN.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.